Aralez Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aralez Pharmaceuticals Inc.
Entyvio strong again for Japanese firm as it raises net profit forecast on lower tax costs. Meanwhile, 'Wave 1' pipeline projects are progressing, with simultaneous development in major markets a key goal.
Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.
Japanese major sheds further non-core assets as it continues to focus on innovation and pay down debt following the Shire acquisition.
Japanese major presses on with post-Shire divestments even after passing strategic target.
- Other Names / Subsidiaries
- Medical Futures Inc.
- POZEN Inc.
- Stellar Pharmaceuticals, Inc. (SLXCF)
- Tribute Pharmaceuticals Inc.